Abstract
Aim:
To investigate the effect of antisense oligodeoxynucleotides (ASODN) targeting Pim-2 on cell proliferation of DU-145 cells.
Methods:
Three ASODN targeting Pim-2 were designed and synthesized. After transfection with ASODN, cell proliferation was analyzed using an MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] assay. In addition, Pim-2 mRNA, protein levels, and cell cycles were examined.
Results:
The ASODN designed and synthesized by our laboratory significantly reduced Pim-2 mRNA level and protein content in DU-145 cells. After transfection with ASODN for 48 h, a marked reduction in cell viability was observed in DU-145 cells in a dose-dependent manner. No remarkable apoptosis occurred in cells treated with ASODN compared with control cells. However, it should be noted that G1 phase arrest was clearly observed in ASODN-treated cells.
Conclusion:
ASODN targeting Pim-2 resulted in a marked reduction in DU-145 cell proliferation, and induction of G1 phase cell cycle arrest is one of the important mechanisms for ASODN to reduce cell growth. Moreover, antisense inhibition of Pim-2 expression provides a new promising therapy target for prostate cancer.
Similar content being viewed by others
Article PDF
References
Gonzalgo ML, Isaacs WB . Molecular pathways to prostate cancer. J Urol 2003; 170: 2444–52.
Maitland NJ, Stanbridge LJ, Dussupt V . Targeting gene therapy for prostate cancer. Curr Pharm Des 2004; 10: 531–55.
Hernandez I, Maddison LA, Wei Y, DeMayo F, Petras T, Li B, et al. Prostate-specific expression of p53 (R172L) differentially regulates p21, Bax, and mdm2 to inhibit prostate cancer progression and prolong survival. Mol Cancer Res 2003; 1: 1036–47.
Pei L, Peng Y, Yang Y, Ling XB, Van Eyndhoven WG, Nguyen KC, et al. PRC17, a novel oncogene encoding a Rab GTPase activating protein, is amplified in prostate cancer. Cancer Res 2002; 62: 5420–54.
Mora LB, Buttner R, Seigne J, Diaz J, Ahmad N, Garica R, et al. Constitutive activation of stats in human prostate tumors and cell lines: direct inhibition of Stat3 signalling induces apoptosis of prostate cancer cells. Cancer Res 2002; 62: 6659–66.
Cuypers HT, Selten G, Quint W, Zijlstra M, Maandag ER, Boelens W, et al. Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell 1984; 37: 141–50.
Eichmann A, Yuan L, Breant C, Alitalo K, Koskinen PJ . Developmental expression of Pim kinases suggests functions also outside of the hematopoietic system. Oncogene 2000; 19: 1215–24.
van der Lugt NM, Domen J, Verhoeven E, Linders K, van der Gulden H, Allen J . Proviral tagging in E mu-myc transgenic mice lacking the Pim-1 proto-oncogene leads to compensatory activation of Pim-2. EMBO J 1995; 14: 2536–44.
Allen JD, Verhoeven E, Domen J, vanderValk M, Berns A . Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc. Oncogene 1997; 15: 1133–41.
Saris CJ, Domen J, Berns A . The Pim-1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG. EMBO J 1991; 10: 655–64.
Yan B, Zemskova, Holder S, Chin V, Kraft A . The PIM-2 kinase phosphorylates BAD on seine 112 and reverses BAD-induced cell death. J Biol Chem 2003; 46: 45358–67.
Chalk AM, Sonnhammer EL . Computational antisense oligo prediction with a neural network model. Bioinformatics 2002; 18: 1567–75.
Shao RG, Cao CX, Shimizu T, O'Connor PM, Kohn KW, Pommier Y . Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res 1997; 57: 4029–35.
Wang Z, Bhattacharya N, Mixter PF, Wei W, Sedivy J, Magnuson NS . Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim Biophys Acta 2002; 1593: 45–55.
Yang SP, Song ST, Tang ZM, Song HF . Optimization of antisense drug design against conservative local motif in simulant secondary structures of HER-2 mRNA and QSAR analysis. Acta Pharmacol Sin 2003; 24: 897–902.
Zheng SX, Zhou LJ, Zhu XZ, Jin YX . Antisense oligodeoxynucleotide inhibits vascular endothelial growth factor in human glioma cells. Acta Pharmacol Sin 2000; 21: 211–4.
Sun HZ, Wu SF, Tu ZH . Knockdown of IGF-IR by antisense oligodeoxynucleotide auguments the sensitivity of bladder cancer cells to mitomycin. Acta Pharmacol Sin 2001; 22: 841–6.
Lahn M, Sundell K, Moore S . Targeting protein kinase C-alpha (PKC-alpha) in cancer with the phosphorothioate antisense oligonucleotide aprinocarsen. Ann NY Acad Sci 2003; 1002: 263–70.
Datta SR, Ranger AM, Lin MZ, Sturgill JF, Ma YC, Cowan CW, et al. Survival factor-mediated BAD phosphorylation raises the mitochondrial threshold for apoptosis. Dev Cell 2002; 3: 631–43.
Plas DR, Thompson CB . Cell metabolism in the regulation of programmed cell death. Trends Endo Met 2002; 13: 74–8.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dai, Jm., Zhang, Sq., Zhang, W. et al. Antisense oligodeoxynucleotides targeting the serine/threonine kinase Pim-2 inhibited proliferation of DU-145 cells. Acta Pharmacol Sin 26, 364–368 (2005). https://doi.org/10.1111/j.1745-7254.2005.00050.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2005.00050.x